| II-01 Noha Abdelgawad Population pharmacokinetics of pyrazinamide in hospitalised TB patients with HIV versus TB outpatients |
| II-02 Mahmoud Abdelwahab Population Pharmacokinetic/Pharmacodynamic Modelling of Clofazimine Effects on QTcF in South African tuberculosis patients |
| II-03 Leticia Arrington Evaluation of IRT-derived disease severity as a predictor of clinical success in critically ill patients with severe antibiotic resistant infections |
| II-04 Fauke Assmus Population pharmacokinetics of benznidazole as monotherapy and in combination with fosravuconazole in adult patients with chronic Chagas disease (BENDITA study) |
| II-05 Rami Ayoun Alsoud Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data |
| II-06 Irina Bondareva Population pharmacokinetics of meropenem in adult intensive care unit (ICU) patients estimated from therapeutic drug monitoring data (TDM) data |
| II-07 Unai Caballero Pharmacokinetic/pharmacodynamic modelling and simulation of the in vitro activity of isavuconazole and echinocandin combination against Candida auris. |
| II-08 Lu Chen Pharmacokinetics of fluconazole in obese and non-obese adults upon a semi-simultaneous oral and IV study design |
| II-09 Palang Chotsiri Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy |
| II-10 Selma El Messaoudi A mechanistic model to characterize the long-term dynamic of HBV markers in Lamivudine and PEG-IFNa treated patients |
| II-11 Teresa Garcia Non-linear binding model of total daptomycin in patients with normal and impaired renal function |
| II-12 Kamunkhwala Gausi Pharmacokinetics of high dose isoniazid among individuals with multidrug-resistant tuberculosis |
| II-13 Victória Etges Helfer Population pharmacokinetic modeling of ceftaroline characterizing tissue distribution following different ceftaroline fosamil infusion regimens to volunteers undergoing muscle and subcutaneous tissue microdialysis |
| II-14 Richard Höglund Pharmacokinetics and pharmacodynamics of ivermectin and its metabolites |
| II-15 Aida Kawuma Rifabutin changes dolutegravir’s half-life but not area under the curve when co-administered |
| II-16 Guillaume Lingas Lassa viral dynamics in macaques treated with favipiravir or ribavirin |
| II-17 Feiyan Liu Modeling inflammatory biomarker dynamics in human LPS challenge studies using delay differential equations |
| II-18 Nele Mueller-Plock Predicting RSV efficacy for moderate and tropical climates considering seasonal differences in RSV force-of-infection – Application of an MBMA and clinical trial simulation framework to support MK-1654 decision making |
| II-19 Anh Duc Pham Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae |
| II-20 Viktor Rognĺs Turn-over model characterizing effect of colistin on serum-creatinine in critically ill patients |
| II-21 Federico Romano Model-based extrapolation of the early bacterial activity (EBA) of bedaquiline-combination regimens for the treatment of pulmonary tuberculosis |
| II-22 Louis Sandra A target-mediated drug disposition model describing plasma and liver pharmacokinetics of JNJ-73763989 in AAV-HBV mice |
| II-23 Hiie Soeorg Prediction of C-reactive protein dynamics during meropenem treatment in very-low-birth-weight neonates with late-onset sepsis or pneumonia |
| II-24 Jesper Sundell Model-based characterization of drug-drug interaction between isoniazid and rifampicin |
| II-25 Lénaďg Tanneau Population pharmacokinetics of delamanid and its main metabolite DM-6705 in patients with multidrug resistant tuberculosis |
| II-26 David Uster Evaluation of four distinct weighting schemes in a model averaging and selection approach in model-informed precision dosing of continuously infused vancomycin |
| II-27 Stijn van Beek Modeling the relationship between plasma and intracellular pharmacokinetics of bedaquiline and its metabolite M2 in South African patients with rifampicin-resistant tuberculosis |
| II-28 Luka Verrest Pharmacokinetic-pharmacodynamic modelling of Leishmania blood parasite kinetics in visceral leishmaniasis patients |
| II-29 Qianwen Wang Determination of risk factors for time to culture conversion in tuberculosis patients receiving novel regimen |
| II-30 Thanaporn Wattanakul Semi-mechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria |
| II-31 Justin Wilkins PK/PD modelling of M5717 in malaria |
| II-32 Tan Zhang A population pharmacokinetic analysis to evaluate the impact of body weight, renal function, and patient status on vancomycin pharmacokinetics |
| II-33 Marcus Baaz Evaluation and Optimization of Model-based Translations in Oncology - From Xenografts to RECIST |
| II-35 Elisa Borella PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population |
| II-36 Aurore CARROT Population K-PD modelling of PSA kinetics in patients with recurrent prostate cancer. |
| II-37 Marc Cerou A model-based approach to evaluate the effect of isatuximab in combination with pomalidomide and dexamethasone using multiple composite endpoints: Application to the ICARIA study in relapsed/refractory multiple myeloma |
| II-38 Pascal Chanu A disease model for Multiple Myeloma developed using Real World Data |
| II-39 Jonathan Chauvin A library of tumor growth and tumor growth inhibition models for the MonolixSuite |
| II-40 Wendy Chu Elucidating the effect of platelet binding on vincristine distribution by a physiologically based pharmacokinetic (PBPK) approach |
| II-41 David Damoiseaux Predictiveness of the human CYP3A4 transgenic mouse model (Cyp3aXAV) for human drug exposure assessed using a population pharmacokinetic approach |
| II-42 Nikki de Rouw Costs of pemetrexed-associated neutropenia and the budget impact of pemetrexed dose individualization |
| II-43 Fernandez Teruel Carlos Population Pharmacokinetics of Capivasertib, a Potent Selective AKT Inhibitor, in Patients with Solid Tumours |
| II-44 David Hodson Non linear mixed effects modelling of tumour interactions with the adaptive immune response during Radiotherapy in combination with anti-PDL1 or Olaparib. |
| II-45 Eman Ibrahim Pharmacokinetic-pharmacodynamic (PK-PD) modeling of leukocyte dynamics and lymph node size in chronic lymphocytic leukaemia patients treated with ibrutinib |
| II-46 Itziar Irurzun Arana Ceralasertib-induced haematological toxicity modelling to support monotherapy Recommended Phase 2 Dose determination |
| II-47 Martin Johnson Long short-term memory recurrent neural networks to predict longitudinal changes in tumour size |
| II-48 Yoshimasa Kobayashi Pharmacometric analysis to justify a higher recommended dose for trastuzumab deruxtecan in the treatment of subjects with metastatic gastric cancer versus breast cancer |
| II-49 Naoki Kotani A model based approach to infer overall survival (OS) in hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (HR+/HER2- mBC) |
| II-50 Nataliya Kudryashova The Markov chain survival modeling platform for cancer burden assessment |
| II-51 Rachael Lawson Development of a time dependent clearance model for busulfan in paediatric patients to investigate dosing adjustment scenarios |
| II-52 Xia Li Population-based Target-Mediated Drug Disposition (TMDD) Pharmacokinetics Model of Daratumumab in Patients With Multiple Myeloma Following Intravenously Daratumumab Monotherapy |
| II-53 Sarah Lobet Target-mediated pharmacokinetics of cetuximab: target occupancy influences progression-free survival |
| II-54 Paolo Magni Reduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach |
| II-55 Luca Marzano Role of tree-based machine learning algorithms in prognostic pattern detection: an Extensive-Disease Small Cell Lung Cancer (ED-SCLC) study |
| II-56 Zinnia Parra-Guillen Mechanistic modeling of a novel oncolytic virus, V937, to describe viral kinetic and dynamic processes following intratumoral and intravenous administration |
| II-57 Clémence Pouzin Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate. |
| II-58 Alicja Puszkiel Optimisation of the dose and schedule of everolimus and sorafenib combination therapy in patients with solid tumors using a PKPD/time-to-event model |
| II-59 Thomas RODIER Population Pharmacokinetic-Pharmacogenetic Analysis of Osimertinib in patients with Non-Small Cell Lung Cancer |
| II-60 Aymara Sancho Semi-mechanistic model for the antitumor response of a combination cocktail of immune-modulators in non-inflamed (cold tumors) |
| II-61 Eduard Schmulenson Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP) |
| II-62 Gianluca Selvaggio Computational analysis of cytokine release following bispecific T-cell engager therapy |
| II-63 Hinke Siebinga A Population Pharmacokinetic Model to Assess Variability in Pharmacokinetics of 177Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients |
| II-64 Alexandra Smirnova Dose dependence of safety of PD-1 and CTLA-4 checkpoint inhibitors: Comparison of normal-normal and binomial-normal hierarchical models for rare events in a Bayesian meta-analysis framework |
| II-65 Alina Volkova The multivariate baseline and longitudinal biomarker analysis for the survival prediction in NSCLC by means of joint modeling |
| II-66 Xuyang SONG Population Pharmacokinetics Modeling of Monalizumab in Cancer Patients with Longitudinal Patient/Disease Characteristics |
| II-67 Maximilian Strobl Adaptive therapy: Leveraging eco-evolutionary principles to improve resistance management in oncology |
| II-68 Elena Tosca A tumor-in-host Dynamic Energy Budget (DEB)-based paradigm for preclinical to clinical translation: predictions of tumor-in-host growth dynamics |
| II-69 Armando Tratenšek Target-mediated drug disposition model of rituximab in patients with diffuse large B-cell lymphoma |
| II-70 Van Thuy Truong A comparison of ordinary differential equation and agent-based approaches to PKPD modelling in oncology |
| II-71 Vianney Tuloup Drug exposure prediction in renal impaired patient: an IMSM approach |
| II-72 Maarten Van Eijk Pharmacokinetic and pharmacodynamic modelling of different oral paclitaxel formulations co-administered with ritonavir. |
| II-73 Elena Vasileva Pharmacokinetic, receptor occupancy and pharmacodynamic (PK/RO/PD) modeling of ALX148, a CD47 blocker |
| II-74 Julie Dudasova A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data |
| II-75 Undine Falkenhagen Reducing QSP models to derive mechanism-based PD models: warfarin-INR as an example |
| II-76 Sergey Gavrilov Survival Model-based Meta-Analysis Framework for the Indirect Comparison of Anti-Cancer Therapy Efficacy |
| II-77 Mohamed Gewily Model Averaging Across Parametric and Non-Parametric Methods as an Aid for Clinical Decision Making |
| II-78 Elham Haem Comparison of the power and type-1 error of composite score models for drug effect detection in clinical trials |
| II-79 Vincent Hurez Development of a systemic lupus erythematosus (SLE) QSP model linking systemic biomarkers to cutaneous clinical score (CLASI) outcomes. |
| II-80 Mutaz Jaber Investigating Components of Residual Unexplained Variability in Nonlinear Mixed-Effect Modeling |
| II-81 Daniel Kaschek Crossing borders from mechanistic QSP to clinical population modeling |
| II-82 Aurélie Lereclus Lithium pharmacometrics: review of population pharmacokinetics models, external evaluation using non compartmental literature data and model’s updating based on straightforward integration of glomerular filtration rate. |
| II-83 Klaus Lindauer Evaluation of random forest as an approach for covariate selection |
| II-84 Dan Lu Machine and deep learning approaches for disease progression modeling: illustration with geographic atrophy |
| II-85 Moustafa M. A. Ibrahim Enhancing Efficiency and Decision Quality in Parkinson’s Disease Drug Trials for LRRK2 Programs Using Item Response Modelling |
| II-86 Rikard Nordgren Pharmpy and assemblerr - Two novel tools to simplify the model building process in NONMEM |
| II-87 Raman Sharma A probabilistic approach to calculating probability of achieving target pharmacological effect levels for a novel orally administered antibacterial chemotherapeutic |
| II-89 Gustaf Wellhagen Item Response Theory-Informed Total Score Analysis |
| II-90 Xiao Zhu Positive allosteric modulators - a challenge for development of QSP models |
